Corient Private Wealth LLC Buys 1,415 Shares of Medpace Holdings, Inc. $MEDP

Corient Private Wealth LLC boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 47.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,409 shares of the company’s stock after buying an additional 1,415 shares during the quarter. Corient Private Wealth LLC’s holdings in Medpace were worth $1,384,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Employees Retirement System of Texas bought a new position in Medpace during the second quarter worth about $36,000. IFP Advisors Inc raised its stake in Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after acquiring an additional 134 shares in the last quarter. Hantz Financial Services Inc. increased its position in shares of Medpace by 5,075.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock worth $65,000 after purchasing an additional 203 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its stake in shares of Medpace by 514.3% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 215 shares of the company’s stock valued at $67,000 after acquiring an additional 180 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MEDP. BMO Capital Markets began coverage on shares of Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective on the stock. TD Cowen increased their target price on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research note on Friday, October 24th. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Rothschild Redb cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. Finally, Jefferies Financial Group lifted their price target on Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $490.82.

Medpace Stock Performance

Shares of MEDP stock opened at $572.00 on Thursday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $626.26. The company has a 50-day simple moving average of $577.81 and a 200 day simple moving average of $477.65. The company has a market capitalization of $16.11 billion, a price-to-earnings ratio of 40.00, a PEG ratio of 2.15 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. During the same period in the previous year, the company posted $3.01 EPS. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity

In related news, CEO August J. Troendle sold 668 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 387,925 shares of company stock worth $233,386,647. Corporate insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.